Yildiz EP, et al. - The data of 21 patients (11 females; mean age, 8.2 years, range: 5.4-15 years) with Dravet syndrome who were treated with stiripentol in between June 2016 and June 2017 were retrospectively studied to analyze the clinical features of cases with the Dravet syndrome and their response to stiripentol. Subjects were found with severe (47%) or moderate (33%) cognitive disabilities and 14% had a mild cognitive disability after a mean duration of 41.2 months (range: 24-64 months) of stiripentol use. Cases with seizure reduction ≥50% were reflected, responders. An important variation in both status epilepticus and age between the groups with normal/mild vs severe/moderate neurocognitive prognoses was observed. They suggested an early treatment for the Dravet syndrome cases with stiripentol as it showed desirable efficiency.